Kara Leanne Bickham MD
Clinical Director, Vaccine Late Stage Development Merck Research Laboratories
Join to View Full Profile
34 Route 403Garrison, NY 10524
Phone+1 845-424-4444
Fax+1 845-424-4664
Dr. Bickham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1994 - 1997
University of Texas Southwestern Medical SchoolClass of 1994
Certifications & Licensure
NY State Medical License 1997 - 2023
Publications & Presentations
PubMed
- Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114...Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder
Vaccine. 2025-02-27 - 1 citationsSafety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies.Timothy J Chapman, Shrita M Patel, Sheryl A Flores, Shengjie Xu, Robert Lupinacci
The Pediatric Infectious Disease Journal. 2023-11-01 - 3 citationsA phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in childre...Marissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, Avy Violari, Pope Kosalaraksa
AIDS. 2023-07-01
Press Mentions
- Merck's Vaxneuvance Lead Departs to Help Develop Rival Vaccine at AffinivaxAugust 9th, 2021
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
